ONCY Oncolytics Biotech Inc.

0.48
+0.05  (+11%)
Previous Close 0.43
Open 0.48
Price To Book 4.32
Market Cap 11,889,796
Shares 25,010,089
Volume 152,430
Short Ratio
Av. Daily Volume 301,502
Stock charts supplied by TradingView

NewsSee all news

  1. Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

    Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous deliveryPelareorep is the only oncolytic virus with meaningful

  2. Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  3. Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  4. Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  5. Oncolytics Biotech(R) Announces Upcoming Conference Participation

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 commencement of dosing announced December 12, 2018.
Pelareorep and Opdivo
Multiple myeloma
Phase 1b interim data due at SITC November 8, 2019 7:00 a.m ET.
Pelareorep and Tecentriq - AWARE-1
Breast cancer
Phase 2 initiation of dosing announced November 26, 2018.
Pelareorep with Keytruda
Pancreatic cancer
Phase 2 trial to be initiated mid-2019.
Pelareorep with Keytruda
Multiple myeloma
Phase 2 trial planned for 1Q 2020 with interim data due 2H 2020.
Pelareorep, paclitaxel and avelumab - BRACELET-1
HR+ / HER2- breast cancer

Latest News

  1. Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

    Across 13 clinical studies and a broad range of cancers, up to 96 percent of tumor samples tested positive for replicating pelareorep virus after intravenous deliveryPelareorep is the only oncolytic virus with meaningful

  2. Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  3. Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  4. Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  5. Oncolytics Biotech(R) Announces Upcoming Conference Participation

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  6. Oncolytics Biotech(R) Receives Nasdaq Notification Letter

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced

  7. Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today

  8. Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 5, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that

  9. Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 4, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced it